checkAd

    Press release Biocartis Group NV  161  0 Kommentare Biocartis Announces Publication of 2020 Annual Report

    PRESS RELEASE: REGULATED INFORMATION      

    1 April 2021, 07:00 CEST

    Biocartis Announces Publication of 2020 Annual Report

    Mechelen, Belgium, 1 April 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2020 annual report. The 2020 annual report provides an overview of the figures and performance of Biocartis for the financial year ended 31 December 2020.

    The report is available as a PDF file and can now be downloaded here from the website of the Company.

    --- END ---

    More information:
    Renate Degrave
    Head of Corporate Communications & Investor Relations Biocartis
    e-mail   rdegrave@biocartis.com
    tel         +32 15 631 729
    mobile   +32 471 53 60 64

    About Biocartis

    Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

    Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.
    This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Press release Biocartis Group NV Biocartis Announces Publication of 2020 Annual Report PRESS RELEASE: REGULATED INFORMATION       1 April 2021, 07:00 CEST Biocartis Announces Publication of 2020 Annual Report Mechelen, Belgium, 1 April 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics …